Evaluation of safety and efficacy of subconjunctival injection of liposomal tacrolimus for allergic conjunctivitis
Ocular allergic disease is an eye inflammation caused by an allergic reaction to substances, like pollen or mould spores. It is a common, chronic condition, with approximately 30% of patients having recurrent episodes. While applying topical eye drops is the current gold standard of treatment, numerous challenges limit its efficacy, including low ocular bioavailability, short duration of action, intensive dosing regimen and patient compliance. A sustainable liposomal drug delivery system through a single subconjunctival injection may overcomes these challenges and has previously demonstrated its safety and efficacy in a mouse model to ameliorate the symptoms and signs of allergic conjunctivitis.
Prof Jodhbir Mehta is leading a team from the Singapore Eye Research Institute, to evaluate the safety and efficacy of subconjunctival injection of liposomal tacrolimus to treat allergic conjunctivitis. The team will first assess the ocular toxicology of the formulation in a rabbit model, to obtain relevant regulatory approval for Phase I and Phase IIa clinical trials. The efficacy and safety of a subconjunctival injection of liposomal tacrolimus will then be validated with a first in human trial to control allergic conjunctivitis. This single injection with long-lasting effects is aimed to be a promising alternative for conventional topical eye drops in the future.
Principal Investigator: Prof. Jodhbir Mehta
Institution: Singapore Eye Research Institute
NHIC Ref: NHIC-I2D-1912242